L. Domanico
Papers
1
Total Citations
6
H-Index
1
About
L. Domanico is a clinical researcher focused on improving prostate cancer management, particularly through the development of more sensitive biomarkers for early detection of recurrence. Their major contribution centers on the evaluation of p2PSA, a prostate-specific antigen isoform, as a predictive tool for biochemical recurrence (BCR) after radical prostatectomy. In a key 2019 prospective cohort study, Domanico demonstrated that p2PSA could detect BCR earlier than traditional total PSA testing, addressing a critical need for timely intervention in recurrent prostate cancer. This work, cited six times, highlights their role in advancing precision oncology by refining post-surgical surveillance. Domanico’s research underscores a commitment to translating molecular markers into clinical practice, offering patients and clinicians a more sensitive window into disease progression. Their findings contribute to the broader effort to reduce overtreatment and improve outcomes in prostate cancer, marking them as a thoughtful contributor to urologic oncology.
Research Focus
Key Achievements
Top Papers
- 1